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Atypical protein kinase C isoforms are serine threonine kinases involved in various patholog-
ical conditions. In recent years, the PKCζ isoform has emerged as an important regulator
of multiple cellular processes operating in cancer. In this review, we will focus on the
PKCζ isoform as an oxidative-sensing kinase involved in cancer-related inflammation and
chemoresistance. We will discuss its nuclear localization and its possible pivotal role in
connecting inflammation with drug resistance.
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INTRODUCTION
The protein kinase C (PKC) family consists of serine/threonine
kinases that can be grouped into three subfamilies based on their
structure and activators (1–3). The proteins within the subfam-
ilies differ in their primary structure, expression patterns, sub-
cellular localization, in vitro activation, and responsiveness to
extra-cellular signals, which suggests the existence of a complex
molecular machinery that regulates the specific sorting of various
isoforms.
Conventional PKCs are calcium dependent and are stimulated
by the second messenger diacylglycerol. Novel PKCs are calcium
independent but are also capable of being stimulated by diacylglyc-
erol. However, atypical PKCs require neither calcium nor diacyl-
glycerol for optimal activity (4) but, rather, are dependent on lipid
components, such as phosphatidylinositols (PIs) (5), phosphatidic
acid (6), arachidonic acid, and ceramide (7).
Inactive PKC is mainly present in the cytosol, whereas acti-
vated PKC is associated with the plasma membrane, nucleus, and
other subcellular compartments (8–11). This differential local-
ization or intracellular redistribution offers an important level
Abbreviations: AOM, azoxymethane; GLP, histone methyltransferase; IκBα, nuclear
factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha; IKK, IKB
kinase; IL-1, interleukin 1; IL-6, interleukin 6; LPS, lipopolysaccharide; MEFs, mouse
embryonic fibroblasts; MEK5, mitogen-activated protein kinase 5; NES nuclear
export signal; NF-κB, nuclear factor kappa B; NLS, nuclear localization signal; PAR-
6, par6 cell polarity protein; PHGDH, 3-phosphoglycerate dehydrogenase; PI3K,
phosphatidylinositol 3-kinase; PIs, phosphatidylinositols; PKC, protein kinase C;
PS, pseudosubstrate; SETD6, SET domain containing 6; Stat3, signal transducer and
activator of transcription 3; TNFα, tumor necrosis factor α.
of regulation of the kinase, favoring interactions with specific
activators or substrates.
Researchers have demonstrated a role of oxidative stress in the
activation and regulation of PKC. Oxidative stress is involved
in the pathogenesis of various degenerative diseases, including
cancer and inflammation (12–15). All of the isoforms of PKC
contain regions in both the N-terminal regulatory domain and
the C-terminal catalytic domain that are susceptible to redox
modifications (2). The sensitivity of PKC regions to redox stress
interferes with the physiological activity of PKCs, and thus, with
their biological effects.
Aberrant regulation or altered expression of PKCs has been
implicated in the development, progression, and maintenance of
the neoplastic phenotype (16, 17). Thus, logical candidates for
the mediation of the pathological transduction of redox stress in
cancer and cancer-related events are the PKCs.
In recent years, the atypical PKCs, particularly the ζ isoform,
have emerged as pivotal regulators of cellular processes oper-
ating in cancer. The aim of this review was to summarize the
available knowledge on the PKCζ isoform in cancer and chemore-
sistance, thereby strengthening the link between PKCζ-dependent
inflammation and chemosensitization.
THE MULTIDOMAIN STRUCTURE OF ATYPICAL PROTEIN
KINASE C ISOFORMS
The atypical PKCs, which form a subgroup within the PKC fam-
ily, consist of isoforms ι, λ, and ζ. PKCι and PKCλ are orthologs
showing 98% overall amino acid sequence identity; hereafter, these
proteins will be referred to as PKCι/λ.
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Closer examination of protein sequence alignments between
the PKC isoforms reveals sequence homology among the different
members of this group. PKCζ and PKCι/λ consist of four func-
tional domains, including a PB1 domain in the N-terminus, a
pseudo-substrate (PS) domain, a C1 domain containing a single
Cys-rich zinc finger motif, and a kinase domain at the C-terminus
(Figure 1A) (10). The classical PKCs differ in their homologous
domains (C2), which appears to be related to the Ca2+ sensi-
tivity of the kinases. Both novel and atypical PKCs lack the C2
homologous domain and, thus, do not require Ca2+ for activa-
tion. In contrast, only the atypical PKCs additionally lack one-half
of the C1 homologous domain (resulting in insensitivity to DAG)
(Figure 1A).
The PB1 domain of PKCζ recognizes the OPCA motifs of PAR-
6, ZIP/p62, and MEK5 (18). The PS domain blocks the substrate-
binding cavity of the kinase domain as an autoinhibitory mech-
anism. The kinase domain of PKCζ and other members includes
an ATP-binding region, an activation loop, a turn motif, and a
hydrophobic motif. The ATP-binding region contains the Lys-281
FIGURE 1 | Redox stress induces PKCζ nuclear translocation, protecting
cells via various apoptotic stimuli. (A) Schematic model of PKC structure.
Representation of the different PKC subfamilies and their structural
domains. The pseudo-substrate (PS) domain blocks the substrate-binding
cavity of the kinase domain as an autoinhibitory mechanism. Conserved
region 1 (C1) confers binding to diacylglycerol (DAG) and phospholipids, and
C2 senses calcium. The PB1 and NLS/NES domains are specific for atypical
PKCs and act as a protein-binding domain and nuclear import-system
domain, respectively. (B) Shows representative images of chimeric
PKCζGFP-expressing HeLa cells in the resting condition (untreated) and
after a 30-min treatment with 1 mM H2O2. PKCζ localizes uniformly
throughout the cytoplasm and is excluded from the nucleus, but upon
oxidative stress challenge, the kinase translocates to the nucleus. Stress
conditions, such the presence of as bacterial infection or cigarette smoke,
favor the accumulation of intracellular ROS, and nuclear redistribution of the
ζ isoform, conferring apoptotic resistance, and thus, chemoresistance.
residue, which is crucial for its kinase activity, while the activation
loop and turn motif contain threonine residues (Thr-410 and Thr-
560), which are phosphorylated upon activation. Finally, a nuclear
localization signal (NLS) sequence is present in atypical PKCs that
allows their rapid import into the nucleus via the formation of an
NLS-importin complex (19), in addition to a short leucine-rich
nuclear export signal (NES) sequence. NES-dependent nuclear
export is inhibited by leptomycin B, which interferes with the bind-
ing of NES to CRM1/exportin 1 (20). The exposure of the NLS in
PKCζ may be regulated by intra-molecular interactions between
the N-terminal region and the catalytic domain of the kinase.
However, these conserved domains confer specific localization
and/or activation inputs for the isotypes.
ATYPICAL PROTEIN KINASE C ISOFORMS IN CANCER
BIOLOGY
In the last decade, atypical PKCs have been implicated in carcino-
genesis. Several studies have reported that PKCι/λ plays a key role
in the promotion of carcinogenesis, both in vitro and in vivo. For
example, PKCι/λ is implicated in Ras signaling, and in particular,
PKCι/λ is required for oncogenic Ras-mediated colon carcinogen-
esis (21). In this study, transgenic mice expressing a constitutively
active form of PKCι/λ displayed a significant number of pre-
neoplastic lesions in the colonic epithelium (21). PKCι/λ is also
important in cancer development and chemotherapy resistance
in non-small cell lung cancers and human colon carcinomas, in
which the kinase is highly expressed. In fact, the introduction of a
dominant negative PKCι/λ mutant or inhibition of its expression
was found to block oncogenic transformation and increase sensi-
tivity to chemotherapeutic agents (22). In summary, PKCι/λ can
be considered an important oncogenic molecule whose expres-
sion can be used as a prognostic marker for several human cancers
(23). As reported above, PKCζ and PKCι/λ are members of the
same group and exhibit 72% sequence homology at the amino
acid level. However, PKCζ and PKCι/λ exhibit distinct functions,
especially during cancer induction and maintenance, where PKCζ
appears to play a controversial role in the neoplastic phenotype.
PKCζ is not activated by diacylglycerol but is stimulated in vitro
by the products of phosphatidylinositol 3-kinase (PI3-K), which
strengthens its role in cellular proliferation. PKCζ interacts directly
with Ras during mitogenic signaling. Ras has been demonstrated
to interact in vitro with the regulatory domain of PKCζ and this
association in vivo is triggered by platelet-derived growth factor
(24).
A number of studies support the clinical relevance of PKCζ
as a tumor suppressor, and a particular mutation in PKCζ has
been found in human cancers (S514F) (25). The ability of PKCζ
overexpression to restrain Ras-induced tumorigenesis is severely
inhibited by the PKCζS514F mutation (26) It has been difficult to
establish whether PKCζ is a pro- or anti-neoplastic protein, as a
panel of human tumors was shown to exhibit contrasting protein
expression levels of PKCζ (26, 27). Furthermore, an anti-apoptotic
effect and, recently, a chemoresistant effect have been attributed to
PKCζ (8).
In the following sections, we will attempt to elucidate the
involvement of the ζ isoform in carcinogenesis and its putative
role as a chemosensitizer.
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PKCζ AND ITS ROLE IN CANCER BIOLOGY
As first described in 1999, increased expression of PKCζ is a charac-
teristic of human prostate cancer (28). A subsequent study found
that the induction of RNA interference against this kinase in PC3
prostate cancer cells reduced their malignant potential (29), con-
firming the critical role of PKCζ in promoting the malignant
prostatic phenotype. Activation of the atypical kinase is not only
necessary but also sufficient to deregulate growth control in mouse
fibroblasts. Using a dominant kinase-defective mutant of PKCζ,
the authors confirmed that the kinase is required for mitogenic
activation in fibroblasts (30). Two studies have shown that PKCζ
can promote the mobility of human MDA-MB-468 breast cancer
cells and pancreatic cancer cells (31, 32). However, in these stud-
ies, the direct involvement of the ζ isoform in cancer progression
was not well described because the authors only used PS peptide
inhibitors and dominant negative mutants of atypical PKC.
Recently, an elegant study performed by Kim et al. showed
how PKCζ induces the phosphorylation of c-Myc and the conse-
quent inhibition of prostate tumorigenesis. Genetic inactivation
of PKCζ in mice was reported to result in invasive prostate carci-
nomas in vivo, which was associated with increased cell growth,
invasion, and metastasis; these findings revealed that the phospho-
rylation of c-Myc on Ser-373 by PKCζ is necessary and sufficient
to repress c-Myc-activity (33). In 2013, a mechanism by which
PKCζ regulates tumor metabolism was described. Here, a lack of
PKCζ was found to be essential for reprograming the metabolism
of tumor cells deprived of glucose through the utilization of glut-
amine. This work highlighted the major involvement of the serine
biosynthetic cascade controlled by 3-phosphoglycerate dehydro-
genase (PHGDH), which was recently shown to be significantly
relevant in cancer (34). A recent study showed that overexpres-
sion of PKCζ inhibits human breast cancer (35), whereas the loss
of this kinase promotes growth and colon tumor formation. To
verify the hypothesis that PKCζ can promote transformed growth
and colon tumor formation, a dominant negative, kinase-deficient
PKCζwas overexpressed in CaCo2 human colon cancer cells, which
stimulated soft agar growth (36). Moreover, the amount of PKCζ
is significantly reduced in azoxymethane (AOM)-induced colon
tumors in rats, and overexpression of PKCζ inhibits the growth of
human MDA-MB-468 breast cancer cells (35).
Based on these reports, it is clear that PKCζ influences tumori-
genesis through different molecular pathways that sustain prolif-
erative signaling, allow evasion of growth suppressors, reprogram
energetic metabolism, and activate invasion and metastasis. Two
other pivotal hallmarks of cancer associated with PKCζ have been
well examined, i.e., resistance to cell death and inflammation, both
of which can be directly linked to the maintenance of the neoplastic
phenotype.
We recently demonstrated that PKCζ induces resistance to
apoptotic agents following its translocation into the nucleus as a
result of oxidative stress (8). Supporting the importance of the role
of the nuclear-PKCζ fraction in chemoresistance, we have shown
that a recombinant nuclear-PKCζ inhibitor restores the apoptotic
susceptibility of doxorubicin-resistant cells (Figure 1B). Indeed,
we have provided direct evidence that doxorubicin-resistant cells
present nuclear-PKCζ accumulation as a consequence of ROS
accumulation (Figure 1B). The involvement of PKCζ through
daunorubicin has also been described, where the activation of
PKCζ triggers the Raf-1/MEK/ERK pathway (37) and inhibits
the sphingomyelin-ceramide pathway, favoring daunorubicin-
dependent chemoresistance (38).
This molecular pathway of chemoresistance is counteracted
by Rituximab treatments, which inhibit the PKCζ/MAPK/mTOR
pathway in follicular cell lymphoma (39). Treatment of lymphoma
cell lines with Rituximab sensitizes the cells to the cytotoxic and
apoptotic effects of therapeutic drugs, due partly to modification
of the synthesis and secretion of anti-apoptotic cytokines impli-
cated in drug resistance, including IL-6, IL-10, and TNFα, and to
the inhibition of NF-κB activity (40, 41).
The “oncogenic behavior” of ROS has been substantiated by a
growing body of evidence (42, 43). The ROS within cells act as sec-
ondary messengers in intracellular signaling cascades that induce
and maintain the oncogenic phenotype of cancer cells, facilitating
mutagenesis, tumor promotion, progression, and chemoresistance
(44, 45). Oxidative stress induces PKC translocation, which is spe-
cific for different isoforms and different cell types. For example,
in mouse embryonic fibroblasts (MEFs) and HeLa cells, oxidative
stress triggers the translocation of the PKCα, β, δ, and ε isoforms
from the cytosol to the plasma membrane (11). Under the same
conditions, PKCζ translocates to the nucleus in MEFs (46) and
HeLa cells (8). We previously described a functional role of nuclear
PKCζ in the regulation of cell viability through the suppression of
apoptotic cell death, thereby shifting the attention of researchers
from cytosolic processes regulated by PKCζ, such as sphingomyeli-
nase inactivation (38) or caspase 9 activation (47), to unknown
nuclear events. These results support the link between the onco-
genic behavior of ROS and the promotion of chemoresistance
via nuclear-PKCζ translocation. Furthermore, this outcome con-
firms that nuclear PKCζ reduces the sensitivity of cancer cells to
chemotherapeutic agents, thus supporting the usefulness of this
kinase as a target for tumor cell chemosensitization.
Studies addressing lung cells and MonoMac6 cells exposed to
cigarette smoke (a cancer inducer) or lipopolysaccharide (LPS,
typically an inflammation inducer) showed that the levels of phos-
phorylated and total PKCζ increased in the nucleus, where phos-
phorylated PKCζ formed a complex with the pro-inflammatory
transcription factor NF-κB (48).
PKCζ AND INFLAMMATION
Over time, tumor cells can become resistant to anti-neoplastic
drugs because molecular escape routes intervene to promote and
maintain cancer integrity, thereby avoiding apoptosis or senes-
cence pathways (49–52). A growing body of evidence indicates a
role of the inflammatory tumor microenvironment in not only
sustaining cancer development but also in cancer responsiveness
and resistance to anticancer therapies (53).
Several chemotherapeutic agents can activate the transcrip-
tion factor NF-κB, thereby promoting chemoresistance through
serine phosphorylation of the inhibitor (IKB kinase, IKK) of
IκBα (54, 55). The functions of NF-κB, including transactivation,
nuclear translocation, and DNA binding, are blocked by its cel-
lular inhibitor, the IκBα protein. An essential component of the
NF-κB pathway is the IKK complex, which phosphorylates IκBα
and triggers its degradation, releasing NF-κB from its cytosolic
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state and promoting its translocation into the nucleus (56). PKCζ
phosphorylates the IKKβ subunit in vitro, possibly through a direct
interaction (Figure 2) (57). In HEK293 cells, PKCζ interacts with
IKKβ at each catalytic domain in a TNFα stimulation-dependent
manner, thereby activating IKK (57). In the lungs of PKCζ-
deficient mice, TNFα-induced IKK activation is repressed (58).
Indeed, PKCζ has been identified as a ceramide-activated pro-
tein kinase that is critical in stress-induced Jun N-terminal kinase
activation and NF-κB translocation (59). In lung carcinogene-
sis, through its ability to activate NF-κB-dependent inflammation,
PKCζ triggers survival pathways (60), and the binding of p62 (also
known as sequestosome-1, required for both the formation and
autophagic degradation of polyubiquitin-containing bodies) to
its targets (61). Indeed, the regulation of NF-κB by the atypical
kinase is relevant to Ras-induced oncogenesis (24, 30). These find-
ings indicate that PKCζ is involved in the IKK signaling complex
and, thus, in NF-κB activation.
Activated-NF-κB promotes cytokine production, including
that of the positive growth-regulator IL-6, favoring chemoresis-
tance. The importance of IL-6 signaling in mediating tumorige-
nesis has been examined in a number of studies, and in in vivo
FIGURE 2 | Fine regulation of NF-κB activation by PKCζ. Schematic
model of the regulation of PKCζ in the inflammatory response and
chromatin remodeling. Activated PKCζ may activate IKK kinase and trigger
IκB degradation. This event precedes NF-κB activation and nuclear
translocation, which makes NF-κB free to interact with elements in the
promoters of inflammatory and survival genes. Indeed, the ζ isoform may
directly interact with and phosphorylate the RelA subunit on Ser311 (P),
leading to increased NF-κB transactivation. The Serine 311 residue is an
important residue for recruiting the CBP coactivator complex. This event
promotes acetylation (Ac) and the activation of cytokine transcription, that
of including IL-6. Under basal conditions, RelA is methylated (Me) by
SETD6, promoting the recruitment of GLP, which leads to repression of
transcription. STAT3 is a key player in mediating inflammation-driven
tumorigenesis, being constitutively activated by chronically high levels of
the pro-inflammatory cytokine IL-6. In tumors, STAT3 is known to enhance
cell survival and proliferation and to promote immune escape and
angiogenesis, invasion, and metastasis. Once activated via tyrosine
phosphorylation by receptor-associated JAK kinases, STAT concentrates in
the nucleus and regulates the expression of target genes. The established
inflammatory tumor microenvironment may contribute to the final outcome
of the neoplastic process.
studies, IL-6 signaling promotes the growth of tumors (62). Within
the tumor microenvironment, IL-6 binds to gp80/gp130, leading
to Janus kinase (JAK) activation and phosphorylation of Stat3,
which regulates the expression of genes that mediate cellular pro-
liferation and prevent apoptosis (Figure 2) (63). PKCζ can control
the production of IL-6. Loss of the kinase in vivo leads to increased
tumorigenicity linked to the overproduction of IL-6 (26), which is
sustained by an inflammatory condition characterized by an M1-
type immunological response (64, 65). IL-6 is a known positive
regulator of growth in human tumors, including liver and lung
tumors (66); however, its production requires NF-κB and PKCζ
(58, 67). IL-1 is known to induce the production of inflamma-
tory cytokines, such as IL-6, through a transcriptional mechanism
dependent on NF-κB activation (68, 69). Finally, PKCζ may reg-
ulate IL-6 promoter activity and transcription through C/EBPβ
regulation via an NF-κB-independent mechanism (26). This find-
ing suggests that PKCζ can both positively regulate NF-κB and, at
the same time, regulate IL-6 transcription through independent
pathways.
One pathway through which NF-κB can be activated is the
Toll-like receptor (TLR) pathway, which occurs through the
adapter protein myeloid differentiation primary response gene
88 (MyD88). NF-κB activation is a result of underlying inflam-
mation or a consequence of the formation of an inflammatory
microenvironment during malignant progression characterized
by up-regulation of the tumor promoting cytokines IL-6 and
TNF-α (70). Activation of the TNF receptor promotes NF-κB
activation in breast cancer cells, leading to increased cancer cell
survival and resistance to ionizing radiation (71). Elevated lev-
els of activated-NF-κB induce cyclin D gene transcription and
cell cycle progression, activation of anti-apoptotic genes bcl-2
and bcl-xL, expression of vascular endothelial growth factor and
consequent tumor angiogenesis, activation of transcription factor
c-myc, metalloproteinase gene expression, and remodeling of the
extra-cellular matrix (72–74).
Cancer-associated p53 mutants acquire significant pro-
inflammatory activity mediated by NF-κB, which promotes both
tumor initiation and tumor progression (75). Mutant p53 iso-
forms exhibit a distinct gain-of-function activity, enforcing a
chronic state of TNF-α-induced NF-κB activation and result-
ing in persistent tissue damage, increased genomic instability,
extended inflammation, and an augmented capacity for mutant
p53-containing cells to evade apoptosis.
Altogether, these data confirm the involvement of the inflam-
matory tumor microenvironment in cancer, thus, attesting to the
contribution of NF-κB activation in chemoresistance.
Recently, Levy and co-workers described a precise mecha-
nism through which NF-κB activation is controlled directly by
Rel A (a subunit of NF-κB) via the methyltransferase SETD6-
mediated methylation of Lys310 (76). The methylated form of
RelA recruits the G9a-related methyltransferase GLP and induces
histone methylation, which represses the chromatin state of
NF-κB-dependent genes, ensuring that they are not transcribed
(Figure 2) (76). This event is coordinated by the PKC-ζ-dependent
phosphorylation of Rel A on Ser31, leading to the release of GLP
and the recruitment of CBP to RelA, followed by the acetyla-
tion of Lys310 and histones, resulting in enhanced transcription
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(Figure 2) (67). This mechanism for the RelA control of NF-κB
in inflammation has been observed in PKCζ-null cells, which are
incapable of mounting an efficient inflammatory response to TNF
and IL-1. The phenotype of the immune system of PKCζ-null mice
further supports the role of PKCζ in controlling NF-κB in vivo
(58). These mice display alterations in the development of sec-
ondary lymphoid organs, showing morphological defects in the
spleen and a reduction in the number of mature B cells (77). Fur-
thermore, they exhibit defects in T helper 2 differentiation, IL-4
production, the nuclear translocation of Stat6 and Rel A (78) and
liver damage, which was due to the depletion of protective signals
in this organ (79).
CONCLUSION
The links between inflammation and cancer have been the subject
of recent studies, as the identification of the underlying molecular
mechanisms may be highly relevant for cancer therapy. The first
link between inflammation and cancer was suggested based on
the use of anti-inflammatory therapies that have shown efficacy in
cancer prevention and treatment (80).
The data described herein indicate that PKCζ is critical in
the generation of inflammatory cytokines that might decide the
final outcome of the neoplastic process. PKCζ exhibits both pro-
inflammatory and anti-inflammatory effects, which complicates
the interpretation of the findings published thus far. However,
data from a study examining the mouse PKCζ-KO phenotype con-
firmed the critical contribution of this kinase to inflammation and
cancer induction. PKCζ could be considered a tumor suppressor,
though other studies have elucidated functional contributions of
the connection of PKCζ to NF-κB and Stat3/IL-6 in carcinogenesis.
The molecular mechanism by which PKCζ participates in multi-
level regulation is strictly dependent on cell type and intracellular
localization.
The data obtained from PKCζ-null mice describe the real bio-
logical contribution of the kinase, at least in part. Genetic ablation
of PKCζ leads to a global, dramatic shutdown of the regulation
of the master regulator proteins associated with inflammation,
cancer, and apoptosis. Here, a limiting factor is that the available
data do not permit the discrimination of individual molecular
mechanisms in which PKCζ is involved.
An emerging concept is that the different functionalities of
PKCζ are related to its intracellular distribution. The nucleus
appears to be a functional site for PKCζ; this localization is regu-
lated by oxidative stress, which is a condition present during both
chemoresistance and inflammation. Nuclear-PKCζ redistribution
reduces the sensitivity of cancer cells to chemotherapeutic agents,
tagging this kinase as a useful target for tumor cell chemosensi-
tization. Understanding the real molecular roles of nuclear PKCζ
will be the next step in defining the specific mechanism that links
oxidative stress, inflammation, and chemoresistance.
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